Title:
ANTIBODY FUSION PROTEIN AND PREPARATION AND USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2024/083226
Kind Code:
A1
Abstract:
An activatable antibody fusion protein, said fusion protein comprising an antibody portion specifically binding to a target, an immunoglobulin Fc portion, a masking portion and a cytokine portion. The present invention further relates to a preparation method for the fusion protein and the use of same in treatment and/or prevention of tumors.
Inventors:
OUYANG XUESONG (CN)
WANG XIAOYAN (CN)
ZHANG HONGJUAN (CN)
WANG XIAOYAN (CN)
ZHANG HONGJUAN (CN)
Application Number:
PCT/CN2023/125682
Publication Date:
April 25, 2024
Filing Date:
October 20, 2023
Export Citation:
Assignee:
BEIJING INNOCARE PHARMA TECH CO LTD (CN)
International Classes:
C07K19/00; A61K47/68; A61P35/00; A61P37/04; C07K14/52; C07K14/54; C07K14/55; C07K16/28; C07K16/30; C12N15/13
Domestic Patent References:
| WO2021202675A1 | 2021-10-07 | |||
| WO2022155541A1 | 2022-07-21 | |||
| WO2021202678A1 | 2021-10-07 |
Foreign References:
| CN113840832A | 2021-12-24 | |||
| CN113166220A | 2021-07-23 | |||
| CN115605504A | 2023-01-13 | |||
| CN112534052A | 2021-03-19 | |||
| CN110606891A | 2019-12-24 |
Other References:
HSU ERIC J., CAO XUEZHI, MOON BENJAMIN, BAE JOONBEOM, SUN ZHICHEN, LIU ZHIDA, FU YANG-XIN: "A cytokine receptor-masked IL2 prodrug selectively activates tumor-infiltrating lymphocytes for potent antitumor therapy", NATURE COMMUNICATIONS, vol. 12, no. 1, 1 December 2021 (2021-12-01), XP055924897, DOI: 10.1038/s41467-021-22980-w
Attorney, Agent or Firm:
CHINA PATENT AGENT (H.K.) LTD. (CN)
Download PDF: